Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.46 |
| ▸ | BRD4 | O60885 | 7/20 | 0.37 |
| ▸ | BRD2 | P25440 | 7/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900246 | 0.95 | QPCT (0.52) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900247 | 0.92 | QPCT (0.48) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900227 | 0.90 | QPCT (0.37) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900208 | 0.87 | QPCT (0.54) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900224 | 0.85 | QPCT (0.48) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900240 | 0.85 | QPCT (0.39) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900187 | 0.83 | QPCT (0.45) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900595 | 0.83 | QPCT (0.41) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900680 | 0.83 | BRD4 (0.41) | QPCTBRD4BRD2BRD3CREBBP | |
| SCHEMBL22900734 | 0.83 | BRD4 (0.41) | QPCTBRD4BRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |